---
title: "Celldex Therapeutics, Inc. (CLDX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CLDX.US.md"
symbol: "CLDX.US"
name: "Celldex Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T06:03:15.186Z"
locales:
  - [en](https://longbridge.com/en/quote/CLDX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CLDX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CLDX.US.md)
---

# Celldex Therapeutics, Inc. (CLDX.US)

## Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.celldex.com](https://www.celldex.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.73)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 213 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -88.56% |  |
| Net Profit YoY | -58.59% |  |
| P/B Ratio | 5.08 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2318877081.90 |  |
| Revenue | 865000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -48.94% | E |
| Profit Margin | -32791.45% | E |
| Gross Margin | -486573.33% | E |
| Revenue YoY | -88.56% | E |
| Net Profit YoY | -58.59% | D |
| Total Assets YoY | -30.86% | E |
| Net Assets YoY | -35.10% | E |
| Cash Flow Margin | 78.32% | C |
| OCF YoY | -88.56% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 10.76% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Celldex Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-88.56%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-58.59%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.08",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2318877081.90",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "865000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-48.94%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-32791.45%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-486573.33%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-88.56%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-58.59%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-30.86%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-35.10%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "78.32%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-88.56%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.76%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.18 | 424/386 | - | - | - |
| PB | 5.08 | 326/386 | 3.74 | 2.72 | 2.15 |
| PS (TTM) | 2680.78 | 300/386 | 1277.04 | 588.56 | 201.23 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 80% |
| Overweight | 2 | 13% |
| Hold | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 30.15 |
| Highest Target | 90.00 |
| Lowest Target | 34.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CLDX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CLDX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CLDX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CLDX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**